Clinical Research

RSS icon
Interview with Nehal Mehta, MD, Penn Medicine, who explains how coronary inflammation can be seen using AI on cardiac CT scans to better risk stratify patients and begin preventive drug therapy.

AI helps cardiologists track new drug's effect on inflammation

The combination of AI and CT helped Nehal Mehta, MD, and colleagues track the performance of a new drug designed to target coronary inflammation. 

doctor examines patient data on their tablet

Moderate aortic stenosis linked to heightened risk of death—should TAVR, surgery be considered?

Researchers tracked data from more than 400,000 patients for a new meta-analysis, presenting their findings in the Journal of the American Heart Association.

When Apple previewed its watchOS 9 update in early June, one of the key features the company highlighted was a new tracking option for atrial fibrillation (AFib) patients. The AFib History feature, approved for patients 22 years and older who have been diagnosed with AFib, was designed to help users gain a better understanding of their symptoms and easily share data with healthcare providers.

Apple Watch AFib feature becomes first-ever digital tool approved by FDA to evaluate medical devices

Healthcare technology companies can now use AFib findings recorded by an Apple Watch to help demonstrate the effectiveness of their devices to the FDA.

Sunil Rao, MD, NYU, explains the DANGER-SHOCK trial at ACC 2024 and how it may help improve cardiogenic shock survival.

Cardiologist Sunil Rao highlights importance of DanGer Shock compared to other cardiogenic shock trials

Sunil Rao, MD, director of interventional cardiology at NYU Langone, says DanGer Shock is a "very, very important study" when it comes to the treatment of cardiogenic shock. 

PAD patients face greater risk of death, complications after a heart attack

PAD and CLI patients who show signs of coronary heart disease may benefit from early treatment, according to a new study of nearly 4 million hospitalizations. 

Confirmed: AFib ablation more beneficial for patients with HFrEF than those with HFpEF

Researchers explored data from nearly 2,500 AFib ablation patients, sharing their findings in JAMA Cardiology.

An 86-year-old patient is showing signs of improvement six months after receiving the world’s first implant of a new-look medical device for treating tricuspid regurgitation (TR), according to new data published in JACC: Cardiovascular Interventions.[1] The device in question, the Tricuspid Flow Optimizer, was developed by Triflo Cardiovascular, a U.S.-based biomedical company founded in 2017 by a team of structural heart specialists.

Cardiologists share update after world’s first implant of new optimizer device for tricuspid regurgitation

The Tricuspid Flow Optimizer was developed by Triflo Cardiovascular, a U.S.-based healthcare technology company founded by structural heart specialists.

Thumbnail

Statin therapy may help HFpEF patients lower their risk of death, heart attack or stroke

All participants were free of ASCVD and had no history of statin use at the start of the study. 

Displaying 81 - 88 of 373

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup